Currently, dual therapies combining PD-1 inhibitors and angiogenesis inhibitors are the recommended first-line treatment for patients with advanced-stage HCC (Reig et al. 2022; Gordan et al. 2020; Su et al. 2022; Bruix et al. 2021). Here, PDCD1 is linked to hepatocellular carcinoma.